Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Clopidogrel
Drug ID BADD_D00504
Description Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.[A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213]
Indications and Usage Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]
Marketing Status approved
ATC Code B01AC04
DrugBank ID DB00758
KEGG ID D07729; D10823; D10824
MeSH ID D000077144
PubChem ID 60606
TTD Drug ID D0N0TZ
NDC Product Code 42543-714; 50090-4918; 52605-083; 16729-218; 0024-1171; 68788-8190; 72578-012; 65977-0037; 52605-082; 63187-362; 63629-4728; 70518-0400; 33342-060; 42543-713; 65162-414; 0093-7314; 16729-219; 61919-007; 67296-1840; 50090-2598; 50090-5781; 0024-1332; 61919-737; 70771-1062; 16714-052; 68071-2813; 68071-4138; 71335-0581
UNII A74586SNO7
Synonyms Clopidogrel | SC 25989C | SC 25990C | SR 25989 | Clopidogrel-Mepha | Clopidogrel Mepha | Clopidogrel Sandoz | Iscover | Clopidogrel Napadisilate | Clopidogrel Hydrochloride | PCR 4099 | PCR-4099 | Clopidogrel Besylate | Clopidogrel Besilate | Clopidogrel, (+)(S)-isomer | Plavix | Clopidogrel Bisulfate
Chemical Information
Molecular Formula C16H16ClNO2S
CAS Registry Number 113665-84-2
SMILES COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sweat gland tumour23.10.01.009; 16.26.01.0090.000043%Not Available
Swelling face23.04.01.018; 10.01.05.018; 08.01.03.1000.000212%Not Available
Swollen tongue10.01.05.015; 23.04.01.014; 07.14.02.0030.000175%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000513%
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.0040.000064%Not Available
Tachypnoea22.02.01.0140.000043%Not Available
Tension19.06.02.0050.000101%Not Available
Therapeutic response increased08.06.01.0210.000178%Not Available
Thrombocytopenia01.08.01.0020.001057%Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Thrombocytosis01.08.02.0010.000032%Not Available
Thrombosis24.01.01.0060.000593%Not Available
Thrombotic microangiopathy24.01.01.013; 20.01.07.004; 01.01.02.0060.000214%Not Available
Thrombotic thrombocytopenic purpura24.07.06.014; 23.06.01.011; 01.08.01.0050.000567%
Tinnitus04.04.01.002; 17.04.07.004--
Tongue discolouration07.14.02.0060.000047%Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.000118%Not Available
Tooth loss12.01.17.026; 07.09.09.0010.000086%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.000053%
Transient ischaemic attack24.04.06.005; 17.08.04.0010.000785%
Tricuspid valve incompetence02.07.05.0010.000032%Not Available
Ulcer08.03.06.0010.000032%Not Available
Unresponsive to stimuli17.02.05.0310.000171%Not Available
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.0060.000717%
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary retention20.02.02.0110.000282%
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.001138%
The 17th Page    First    Pre   17 18 19 20 21    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene